Health care utilization and costs in type 2 diabetes mellitus and their association with renal impairment

Postgraduate Medicine

Volumn 124, Issue 2, 2012, Pages 77-91

  Burke, James ^a   Kovacs, Birgit ^b   Borton, Leigh ^a   Sander, Stephen ^b  

^a OPTUM   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Chronic renal failure; Claims analysis; Health care costs; Type 2 diabetes mellitus

Indexed keywords

CREATININE; INSULIN;

ADULT; AGED; AMBULATORY CARE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG COST; EMERGENCY CARE; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; RETROSPECTIVE STUDY; UNITED STATES;

EID: 84858807155     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2012.03.2539     Document Type: Article

References (40)

1. US Centers for Disease Control and Prevention. National diabetes fact sheet. http://www.cdc.gov/diabetes/pubs/factsheet11.htm. Accessed October 12, 2011.
2. Shogbon AO, Levy SB. Intensive glucose control in the management of diabetes mellitus and inpatient hyperglycemia. Am J Health Syst Pharm. 2010;67(10):798-805.
3. DCCT Research Group. Diabetes Control and Complications Trial (DCCT): results of feasibility study. Diabetes Care. 1987;10(1):1-19.
4. Karter AJ, Moffet HH, Liu J, et al. Achieving good glycemic control: initiation of new antihyperglycemic therapies in patients with type 2 diabetes from the Kaiser Permanente Northern California Diabetes Registry. Am J Manag Care. 2005;11(4):262-270.
5. Kuritzky L, Epstein BJ, Lavernia F. How to obtain appropriate type 2 diabetes control in the first 180days of treatment initiation. Postgrad Med. 2010;122(3):33-42.
6. Nadeau DA. Partnering with patients to improve therapeutic outcomes: incretin-based therapy for type 2 diabetes. Postgrad Med. 2010;122(3):7-15.
7. Freeman JS. New therapeutic options: management strategies to optimize glycemic control. J Am Osteopath Assoc. 2010;110(3suppl 2):S15-S20.
8. Katon W, Russo J, Lin EH, et al. Diabetes and poor disease control: is comorbid depression associated with poor medication adherence or lack of treatment intensification? Psychosom Med. 2009;71(9):965-972.
9. American Diabetes Association. Economic costs of diabetes in the US in 2007. Diabetes Care. 2008;31(3).
10. Pelletier EM, Shim B, Ben-Joseph R, Caro JJ. Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis. Pharmacoeconomics. 2009; 27(6):479-490.
11. American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care. 2007;30(suppl 1):S4-S41.
12. Lin R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care. 2010;33(8):1872-1894.
13. Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther. 2009;31(11):2608-2617.
14. Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003;289(24):3273-3277.
15. American Diabetes Association. Standards of medical care in diabetes, 2006. Diabetes Care. 2006;29(suppl 1):S4-S42.
16. National Kidney Foundation. KDOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. 2010. http://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm. Accessed October 12, 2011.
17. Hueston WJ, Scibelli S, Mainous AG 3rd. Use of microalbuminuria testing in persons with type 2 diabetes: are the right patients being tested? J Fam Pract. 2001;50:669-673.
18. Weiner DE. Public health consequences of chronic kidney disease. Clin Pharmacol Ther. 2009;86(5):566-569.
19. National Kidney Foundation. Kidney learning solutions: GFR, chronic kidney disease. http://www.kidney.org/professionals/KLS/gfr.cfm#43.Accessed October 12, 2011.
20. Weiner DE. Causes and consequences of chronic kidney disease: implications for managed health care. J Manag Care Pharm. 2007;13: S1-S9.
21. Selby JV, Ray GT, Zhang D, Colby CJ. Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care. 1997;20(9):1396-1402.
22. Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med. 1999;159(16):1873-1880.
23. Health Insurance Portability and Accountability Act of 1996. Public Law 104-191, 104th Congress. http://www.cms.hhs.gov/HIPAAGenInfo/Downloads/HIPAALaw.pdf. Accessed October 12, 2011.
24. Rule AD, Larson TS, Berstralh EJ, et al. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med. 2004;141:929-937.
25. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Medical Care. 2005;43(11):1130-1139.
26. US Department of Labor, Bureau of Labor Statistics. Consumer Price Index. Chained Consumer Price Index for all urban consumers (C-CPI-U) 1999-2008, Medical Care. Series ID: SUUR0000SAM. Washington, DC: US Department of Labor, Bureau of Labor Statistics, 2008. http://data.bls.gov/cgi-bin/surveymost?su. Accessed October 12, 2011.
27. Frytak JF, Henk JH, Zhao Y, Bowman L, Flynn JA, Nelson M. Health services utilization among Alzheimer's subjects: evidence from managed care. Alzheimers Dement. 2008;4(5):361-367.
28. Basu A, Manning WG. Issues for the next generation of health care cost analyses. Med Care. 2009;47(7suppl 1):S109-S114.
29. Mihaylova B, Briggs A, O'Hagan A, Thompson SG. Review of statistical methods for analysing healthcare resources and costs. Health Econ. 2011;20(8):897-916.
30. Blough DK, Madden CW, Hornbrook MC. Modeling risk using generalized linear models. J Health Econ. 1999;18(2):153-171.
31. Sobngwi E, Enoru S, Ashuntantang G, et al. Day-to-day variation of insulin requirements of patients with type 2 diabetes and end-stage renal disease undergoing maintenance hemodialysis. Diabetes Care. 2010;33(7):1409-1412.
32. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49(suppl 2):S1-S179.
33. Joyce AT, Iacoviello JM, Nag S, et al. End-stage renal disease-associated managed care costs among patients with and without diabetes. Diabetes Care. 2004;27(12):2829-2835.
34. Laliberté F, Bookhart BK, Vekeman F, et al. Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective. J Manag Care Pharm. 2009;15(4):312-322.
35. Pereira JB. Overcoming barriers to the early detection and treatment of chronic kidney disease and improving outcomes for end-stage renal disease. Am J Manag Care. 2002;8(4suppl):S122-S135.
36. Zanchetti A, Stella A. Cardiovascular disease and the kidney: an epidemiologic overview. J Cardiovasc Pharmacol. 1999;33(suppl 1): S1-S6.
37. Cohen JT, Jasimuddin SK, Tommasulo BC, et al. Underdiagnosis of chronic kidney disease in the nursing home population. J Am Geriatr Soc. 2009;57(6):1123-1124.
38. Murphree DD, Thelen SM. Chronic kidney disease in primary care. J Am Board Fam Med. 2010;23(4):542-550.
39. Black C, Sharma P, Scotland G, et al. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. Health Technol Assess. 2010;14(21):1-184.
40. Palmer AJ, Valentine WJ, Chen R, et al. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrol Dial Transplant. 2008;23(4):1216-1223.